Any feedback?
Literature summary for 3.4.14.5 extracted from
- Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (2007), Curr. Med. Res. Opin., 23, 1131-1138.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | the dipeptidyl peptidase-IV inhibitor vildagliptin improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell responsiveness to glucose. Co-administration of warfarin (a vitamin K antagonist widely used for long-term prevention of thrombosis) does not alter the pharmacokinetics of vildagliptin | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| vildagliptin | - |
Homo sapiens |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| dipeptidyl peptidase-IV | - |
Homo sapiens |
| DPP-4 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
